Kidney Cancer

Latest News

Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC

May 15th 2024

The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.

Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
Grant awarded to aid development of allogeneic CAR T treatment for RCC

April 29th 2024

siRNA drug therapy shows promise in clear cell renal cell carcinoma
siRNA drug therapy shows promise in clear cell renal cell carcinoma

April 25th 2024

Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC

April 19th 2024

Toripalimab plus axitinib approved in China for renal cell carcinoma
Toripalimab plus axitinib approved in China for renal cell carcinoma

April 11th 2024

Video Series
Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.